Comparative Pharmacology
Head-to-head clinical analysis: BENADRYL PRESERVATIVE FREE versus TAVIST 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENADRYL PRESERVATIVE FREE versus TAVIST 1.
BENADRYL PRESERVATIVE FREE vs TAVIST-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenhydramine competitively antagonizes histamine at H1-receptors on effector cells, leading to relief of allergic symptoms. It also possesses anticholinergic, antiemetic, sedative, and local anesthetic effects.
TAVIST-1 (clemastine fumarate) is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
25-50 mg IV/IM every 4-6 hours as needed; maximum single dose 100 mg, maximum daily dose 400 mg.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
Terminal elimination half-life: 4-8 hours (mean ~5 hours). Prolonged in hepatic impairment (up to 2-fold) and elderly (7-12 hours).
Terminal half-life 12–15 hours; clinical dosing interval every 12 hours.
Primarily renal (90% as metabolites and unchanged drug); ~1% excreted in feces via bile. Unchanged diphenhydramine accounts for <5% of urinary recovery.
Primarily renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; minor via feces.
Category C
Category C
Antihistamine
Antihistamine